S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML

Detalles Bibliográficos
Autores principales: Gyurkocza, Boglarka, Seropian, Stuart, Choe, Hannah, Litzow, Mark, Abboud, Camille, Koshy, Nebu, Stiff, Patrick, Tomlinson, Benjamin, Abhyankar, Sunil, Foran, James M, Hari, Parameswaran, Chen, George, Al-Kadhimi, Zaid, Kebriaei, Partow, Sabloff, Mitchell, Orozco, Johnnie, Jamieson, Katarzyna, Silverman, Margarida, Van Besien, Koen, Schuster, Michael, Law, Arjun, Abedin, Sameem, Larkin, Karilyn, Rowley, Scott, Munshi, Pashna, Cook, Rachel, Mayer, Sebastian, Levy, Moshe Yair, Lazarus, Hillard, Sandmaier, Brenda, Reddy, Vijay, Spross, Jennifer, Mcnamara, Kathleen, Haeuber, Elaina, Vusirikala, Madhuri, Nahar, Akash, Pagel, John, Giralt, Sergio, Desai, Avinash, Nath, Rajneesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428510/
http://dx.doi.org/10.1097/01.HS9.0000967904.29417.23
_version_ 1785090487474978816
author Gyurkocza, Boglarka
Seropian, Stuart
Choe, Hannah
Litzow, Mark
Abboud, Camille
Koshy, Nebu
Stiff, Patrick
Tomlinson, Benjamin
Abhyankar, Sunil
Foran, James M
Hari, Parameswaran
Chen, George
Al-Kadhimi, Zaid
Kebriaei, Partow
Sabloff, Mitchell
Orozco, Johnnie
Jamieson, Katarzyna
Silverman, Margarida
Van Besien, Koen
Schuster, Michael
Law, Arjun
Abedin, Sameem
Larkin, Karilyn
Rowley, Scott
Munshi, Pashna
Cook, Rachel
Mayer, Sebastian
Levy, Moshe Yair
Lazarus, Hillard
Sandmaier, Brenda
Reddy, Vijay
Spross, Jennifer
Mcnamara, Kathleen
Haeuber, Elaina
Vusirikala, Madhuri
Nahar, Akash
Pagel, John
Giralt, Sergio
Desai, Avinash
Nath, Rajneesh
author_facet Gyurkocza, Boglarka
Seropian, Stuart
Choe, Hannah
Litzow, Mark
Abboud, Camille
Koshy, Nebu
Stiff, Patrick
Tomlinson, Benjamin
Abhyankar, Sunil
Foran, James M
Hari, Parameswaran
Chen, George
Al-Kadhimi, Zaid
Kebriaei, Partow
Sabloff, Mitchell
Orozco, Johnnie
Jamieson, Katarzyna
Silverman, Margarida
Van Besien, Koen
Schuster, Michael
Law, Arjun
Abedin, Sameem
Larkin, Karilyn
Rowley, Scott
Munshi, Pashna
Cook, Rachel
Mayer, Sebastian
Levy, Moshe Yair
Lazarus, Hillard
Sandmaier, Brenda
Reddy, Vijay
Spross, Jennifer
Mcnamara, Kathleen
Haeuber, Elaina
Vusirikala, Madhuri
Nahar, Akash
Pagel, John
Giralt, Sergio
Desai, Avinash
Nath, Rajneesh
author_sort Gyurkocza, Boglarka
collection PubMed
description
format Online
Article
Text
id pubmed-10428510
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104285102023-08-17 S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML Gyurkocza, Boglarka Seropian, Stuart Choe, Hannah Litzow, Mark Abboud, Camille Koshy, Nebu Stiff, Patrick Tomlinson, Benjamin Abhyankar, Sunil Foran, James M Hari, Parameswaran Chen, George Al-Kadhimi, Zaid Kebriaei, Partow Sabloff, Mitchell Orozco, Johnnie Jamieson, Katarzyna Silverman, Margarida Van Besien, Koen Schuster, Michael Law, Arjun Abedin, Sameem Larkin, Karilyn Rowley, Scott Munshi, Pashna Cook, Rachel Mayer, Sebastian Levy, Moshe Yair Lazarus, Hillard Sandmaier, Brenda Reddy, Vijay Spross, Jennifer Mcnamara, Kathleen Haeuber, Elaina Vusirikala, Madhuri Nahar, Akash Pagel, John Giralt, Sergio Desai, Avinash Nath, Rajneesh Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428510/ http://dx.doi.org/10.1097/01.HS9.0000967904.29417.23 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Sessions
Gyurkocza, Boglarka
Seropian, Stuart
Choe, Hannah
Litzow, Mark
Abboud, Camille
Koshy, Nebu
Stiff, Patrick
Tomlinson, Benjamin
Abhyankar, Sunil
Foran, James M
Hari, Parameswaran
Chen, George
Al-Kadhimi, Zaid
Kebriaei, Partow
Sabloff, Mitchell
Orozco, Johnnie
Jamieson, Katarzyna
Silverman, Margarida
Van Besien, Koen
Schuster, Michael
Law, Arjun
Abedin, Sameem
Larkin, Karilyn
Rowley, Scott
Munshi, Pashna
Cook, Rachel
Mayer, Sebastian
Levy, Moshe Yair
Lazarus, Hillard
Sandmaier, Brenda
Reddy, Vijay
Spross, Jennifer
Mcnamara, Kathleen
Haeuber, Elaina
Vusirikala, Madhuri
Nahar, Akash
Pagel, John
Giralt, Sergio
Desai, Avinash
Nath, Rajneesh
S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
title S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
title_full S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
title_fullStr S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
title_full_unstemmed S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
title_short S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
title_sort s248: sierra trial results with a targeted radiotherapy, iomab-b, a myeloablative conditioning with reduced intensity tolerability yields high cr, long term survival in hsct ineligible active r/r aml
topic Oral Sessions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428510/
http://dx.doi.org/10.1097/01.HS9.0000967904.29417.23
work_keys_str_mv AT gyurkoczaboglarka s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT seropianstuart s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT choehannah s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT litzowmark s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT abboudcamille s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT koshynebu s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT stiffpatrick s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT tomlinsonbenjamin s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT abhyankarsunil s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT foranjamesm s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT hariparameswaran s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT chengeorge s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT alkadhimizaid s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT kebriaeipartow s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT sabloffmitchell s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT orozcojohnnie s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT jamiesonkatarzyna s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT silvermanmargarida s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT vanbesienkoen s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT schustermichael s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT lawarjun s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT abedinsameem s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT larkinkarilyn s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT rowleyscott s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT munshipashna s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT cookrachel s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT mayersebastian s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT levymosheyair s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT lazarushillard s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT sandmaierbrenda s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT reddyvijay s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT sprossjennifer s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT mcnamarakathleen s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT haeuberelaina s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT vusirikalamadhuri s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT naharakash s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT pageljohn s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT giraltsergio s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT desaiavinash s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml
AT nathrajneesh s248sierratrialresultswithatargetedradiotherapyiomabbamyeloablativeconditioningwithreducedintensitytolerabilityyieldshighcrlongtermsurvivalinhsctineligibleactiverraml

Ejemplares similares